LXEO LEXEO THERAPEUTICS INC

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that Lexeo management will participate in corporate presentations and fireside chats at the following investor conferences:

  
 H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024 at 10:00 AM ET
 Baird 2024 Global Healthcare Conference on Tuesday, September 10, 2024 at 1:25 PM ET
 Cantor 2024 Global Healthcare Conference on Wednesday, September 18, 2024 at 11:30 AM ET
 Chardan’s 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 2:30 PM ET
  

The events will be webcast live under the tab in the Investors section of our website. Replays of the webcasts will be available on the website following the presentations.

About Lexeo Therapeutics

Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease are treated. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimer’s disease programs.

Media Response:

Investor Response:

Stephen Jasper

(858) 525-2047



EN
05/09/2024

Underlying

LXEOLEXEO THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LEXEO THERAPEUTICS INC

 PRESS RELEASE
Free
LXEO LEXEO THERAPEUT...

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of...

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference Late-breaking oral presentation to highlight safety and efficacy of LX1001 across four dose cohorts NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that interim data from the ongoing Phase 1/2 trial () of LX1001 have been sele...

October 22, 2024 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 46.28
ALGT ALLEGIANT TRAVE...
TDS Telephone and D... ... (+36)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ALGT ALLEGIANT TRAVEL CO
TDS TELEPHONE AND DATA SYSTEMS INC.
JBLU JETBLUE AIRWAYS CORPORATION
MDU MDU RESOURCES GROUP INC
CMA COMERICA INCORPORATED
USM UNITED STATES CELLULAR CORP
VALU VALUE LINE INC.
CIA CITIZENS INC. CL A
AIRG AIRGAIN
LW LAMB WESTON HOLDINGS INC.
ROKU ROKU INC. CLASS A
RDVT RED VIOLET
EAT AMREST HOLDINGS SE
NEON NEONODE INC.
PTON PELOTON INTERACTIVE INC. CLASS A
CRMD CORMEDIX INC.
PLRX PLIANT THERAPEUTICS
RNA AVIDITY BIOSCIENCES
ALKT ALKAMI TECHNOLOGY INC
ULCC FRONTIER GROUP HLDGS INC
RELY REMITLY GLOBAL INC
SNCY SUN COUNTRY AIRLINES HLDGS INC
NN NEXTNAV INC
OPFI OPPFI INC
AURA AURA BIOSCIENCES INC
TYRA TYRA BIOSCIENCES INC
MLYS MINERALYS THERAPEUTICS INC
ELVN IMARA INC
SLG SL GREEN REALTY CORP.
WGS GENEDX HOLDINGS CORP.
LXEO LEXEO THERAPEUTICS INC
GDLC GRAYSCALE DIGITAL LARGE CAP FD COM
LB LANDBRIDGE COMPANY LLC
FOA FINANCE OF AMERICA COMPANIES INC.
TECX TD GLOBAL TECHNOLOGY LEADERS CAD HEDGED INDEX ETF
RDDT REDDIT INC
10/21/24 October 21, 2024 1 EN
 PRESS RELEASE
Free
LXEO LEXEO THERAPEUT...

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Lexeo Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that Lexeo management will participate in corporate presentations and fireside chats at the following investor conferences:    H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024 at 10:00 AM ET Baird 2024 Global Healthcare Co...

September 5, 2024 1 EN
 PRESS RELEASE
Free
LXEO LEXEO THERAPEUT...

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and O...

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures Recently initiated formal engagements with FDA on surrogate endpoints for LX2006 registrational study; expects to provide update by end of year Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently recruit...

August 12, 2024 1 EN
 PRESS RELEASE
Free
LXEO LEXEO THERAPEUT...

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data ...

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline >10% reduction in LVMI at 12 months in 75% of participants with elevated LVMI at baseline Sustained and consistent improvements in other key measures of cardiac status, including left ventricular wall thickness and troponin I, in majority of participants at 12 months Increased post-treat...

July 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch